September 14 2010 Issue

1) Muscular dystrophy and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Richard Finkel about his paper on muscular dystrophy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about anti-NMDA receptor antibody encephalitis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs for the next part of our discussion on aphasias for our Lesson of the Week. Over the subsequent two weeks, we will continue to highlight the disorders of language. The participants had nothing to disclose except Drs. Dimberg, Finkel, Overman, Espay and Josephs. Dr. Dimberg serves as an editorial board member of AANEM Nerve and Muscle Junction Podcasts and as part of the Neurology® Podcast Panel, has received honoraria from ePocrates.com and Harris Interactive. Dr. Finkel serves on advisory boards for PTC Therapeutics, Inc., DuchenneConnect, Families of SMA, the National Fabry Disease Foundation, and TREAT-NMD; has received travel expenses for lectures not funded by industry; receives research support from PTC Therapeutics, Inc., Genzyme Corporation, Santhera Pharmaceuticals, the NIH (U54 AR0526446-03 [Co-I] and 1U54 NS0657-12-01 [Co-I]), the SMA Foundation, the Muscular Dystrophy Association, and the Foundation for the Eradication of Duchenne; and his spouse serves on the editorial board of Arthritis Research and Therapy, holds and has received license fees for numerous patents related to T cell activation and HIV, and receives research support from Merck Serono and the NIH in the field of T cell activation, HIV and genomics of juvenile arthritis.Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Josephs is funded by R01- DC010367 (PI), the Dana Foundation (PI), and the Morris K. Udall PD Research Center of Excellence NIH/NINDS P50 NS40256 (Co-I).